In a report released today, Constantine Davides from EF Hutton maintained a Buy rating on Longeveron (LGVN – Research Report), with a price target of $12.50. The company’s shares closed yesterday at $3.30.
Davides covers the Healthcare sector, focusing on stocks such as Acer Therapeutics, VolitionRX, and Acasti Pharma. According to TipRanks, Davides has an average return of -8.3% and a 42.86% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Longeveron with a $13.25 average price target.
See the top stocks recommended by analysts >>
LGVN market cap is currently $75.04M and has a P/E ratio of -3.75.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LGVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Longeveron LLC is a biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).
Read More on LGVN:
- UPDATE — Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones
- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones
- Longeveron provides corporate update, 2023 strategic priorities
- Longeveron to Participate in Upcoming 2022 Investor Conferences
- Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results
